BioMarin to Acquire Alesta Therapeutics for Lead ALE1 Program
BioMarin PharmaceuticalSigSignificance2.83SenSentiment+4.02EnvEnvironment0.00SocSocial+2.32GovGovernance+0.87
BioMarin entered into a definitive agreement to acquire Alesta Therapeutics to gain ALE1, a lead clinical-stage asset with potential as a first oral therapy for hypophosphatasia. Boards of both companies approved the deal, expected to close this quarter subject to customary conditions. ALE1 is in an ongoing Phase 1/2a trial, and Alesta will spin out non-ALE1 assets prior to closing with employee transfers to the spinout entity.
Coverage (3)
- BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment (cnbc.com)
- BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline (prnewswire.com)
- BioMarin acquires experimental drug for rare bone disorder in $275M deal (biopharmadive.com)